

Antonin Levy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9478762/publications.pdf>

Version: 2024-02-01

152
papers

4,280
citations

101543

36
h-index

138484

58
g-index

177
all docs

177
docs citations

177
times ranked

6510
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 671-680.	10.7	318
2	Definition of Synchronous Oligometastatic Non-“Small Cell Lung Cancer” A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2109-2119.	1.1	189
3	Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials. <i>Clinical Cancer Research</i> , 2014, 20, 246-252.	7.0	144
4	Radiation-enhanced cell migration/invasion process: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 133-142.	4.4	140
5	Targeting a cornerstone of radiation resistance: Cancer stem cell. <i>Cancer Letters</i> , 2012, 322, 139-147.	7.2	128
6	Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?. <i>Journal of Clinical Oncology</i> , 2011, 29, 1728-1735.	1.6	120
7	Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). <i>European Journal of Cancer</i> , 2019, 114, 117-127.	2.8	120
8	Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial. <i>European Journal of Cancer</i> , 2016, 68, 156-162.	2.8	113
9	Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives. <i>Cancer Treatment Reviews</i> , 2015, 41, 844-852.	7.7	110
10	Can immunostimulatory agents enhance the abscopal effect of radiotherapy?. <i>European Journal of Cancer</i> , 2016, 62, 36-45.	2.8	105
11	Radiotherapy-“immunotherapy combinations” perspectives and challenges. <i>Molecular Oncology</i> , 2020, 14, 1529-1537.	4.6	94
12	Targeting Head and Neck Cancer Stem Cells to Overcome Resistance to Photon and Carbon Ion Radiation. <i>Stem Cell Reviews and Reports</i> , 2014, 10, 114-126.	5.6	92
13	Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status. <i>Oral Oncology</i> , 2017, 71, 150-155.	1.5	92
14	Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. <i>Annals of Oncology</i> , 2013, 24, 2834-2838.	1.2	78
15	Interest of diffusion-weighted echo-planar MR imaging and apparent diffusion coefficient mapping in gynecological malignancies: A review. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 33, 1020-1027.	3.4	74
16	Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. <i>European Journal of Cancer</i> , 2018, 93, 37-46.	2.8	69
17	Primary Extremity Soft Tissue Sarcomas: Does Local Control Impact Survival?. <i>Annals of Surgical Oncology</i> , 2017, 24, 194-201.	1.5	64
18	Innate immune receptor NOD2 mediates LGR5 ⁺ intestinal stem cell protection against ROS cytotoxicity via mitophagy stimulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1994-2003.	7.1	63

#	ARTICLE	IF	CITATIONS
19	Radiation therapy and immunotherapy: Implications for a combined cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 278-287.	4.4	61
20	Optimize and refine therapeutic index in radiation therapy: Overview of a century. <i>Cancer Treatment Reviews</i> , 2016, 45, 58-67.	7.7	60
21	Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. <i>European Journal of Cancer</i> , 2018, 105, 19-27.	2.8	56
22	Targeted therapy-induced radiation recall. <i>European Journal of Cancer</i> , 2013, 49, 1662-1668.	2.8	55
23	Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. <i>European Journal of Cancer</i> , 2016, 66, 91-94.	2.8	54
24	Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. <i>Cancer Medicine</i> , 2014, 3, 1517-1526.	2.8	53
25	Defining Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Systematic Review. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2053-2061.	1.1	52
26	External Beam Accelerated Partial-Breast Irradiation Using 32 Gy in 8 Twice-Daily Fractions: 5-Year Results of a Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e271-e277.	0.8	50
27	Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 1223-1229.	1.2	45
28	Radiation Therapy for Hypersalivation: A Prospective Study in 50 Amyotrophic Lateral Sclerosis Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 589-595.	0.8	44
29	Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 823-831.	2.0	44
30	Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2016, 62, 114-121.	1.5	43
31	Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 1683-1690.	1.6	43
32	Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. <i>European Journal of Cancer</i> , 2013, 49, 1898-1904.	2.8	42
33	Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. <i>EClinicalMedicine</i> , 2019, 17, 100215.	7.1	42
34	Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics?. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 699-712.	5.9	41
35	Epithelioid Sarcoma: Need for a Multimodal Approach to Maximize the Chances of Curative Conservative Treatment. <i>Annals of Surgical Oncology</i> , 2014, 21, 269-276.	1.5	40
36	Accuracy of Diffusion-Weighted Echo-Planar MR Imaging and ADC Mapping in the evaluation of residual Cervical Carcinoma after radiation therapy. <i>Gynecologic Oncology</i> , 2011, 123, 110-115.	1.4	39

#	ARTICLE	IF	CITATIONS
37	Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse. <i>Cancer Treatment Reviews</i> , 2016, 50, 240-246.	7.7	38
38	Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy. <i>Oncolmunology</i> , 2017, 6, e1341030.	4.6	36
39	Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial. <i>Radiotherapy and Oncology</i> , 2015, 114, 415-416.	0.6	35
40	EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. <i>European Journal of Cancer</i> , 2019, 122, 109-114.	2.8	33
41	Metformin for non-small cell lung cancer patients: Opportunities and pitfalls. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 41-47.	4.4	32
42	Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?. <i>European Respiratory Journal</i> , 2018, 51, 1701737.	6.7	32
43	Risk factors for burnout among caregivers working in nursing homes. <i>Journal of Clinical Nursing</i> , 2018, 27, e147-e153.	3.0	32
44	Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review. <i>International Journal of Oncology</i> , 2014, 44, 5-16.	3.3	31
45	Brain Radiation Necrosis: Current Management With a Focus on Non-small Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2018, 8, 336.	2.8	26
46	Radiotherapy for Trachealâ€“Bronchial Cystic Adenoid Carcinomas. <i>Clinical Oncology</i> , 2018, 30, 39-46.	1.4	24
47	Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?. <i>Oral Oncology</i> , 2016, 59, 50-57.	1.5	23
48	Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 130, 89-96.	0.6	23
49	Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research. <i>Clinical Cancer Research</i> , 2020, 26, 4723-4736.	7.0	23
50	Whole brain radiotherapy: Prognostic factors and results of a radiation boost delivered through a conventional linear accelerator. <i>Radiotherapy and Oncology</i> , 2011, 99, 214-217.	0.6	22
51	Is preoperative radiotherapy suitable for all patients with primary soft tissue sarcoma of the limbs?. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1648-1654.	1.0	22
52	Uterine and Ovary Carcinosarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 272-277.	1.3	21
53	Contribution of image-guided adaptive brachytherapy to pelvic nodes treatment in locally advanced cervical cancer. <i>Brachytherapy</i> , 2017, 16, 366-372.	0.5	20
54	Late toxicity of brachytherapy after female genital tract tumors treated during childhood: Prospective evaluation with a long-term follow-up. <i>Radiotherapy and Oncology</i> , 2015, 117, 206-212.	0.6	19

#	ARTICLE	IF	CITATIONS
55	Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion. <i>European Journal of Cancer</i> , 2019, 123, 28-35.	2.8	19
56	The Current Role of Whole Brain Radiation Therapy in Non-“Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1467-1477.	1.1	18
57	Pharmacological modulation of radiation-induced oral mucosal complications. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2018, 22, 429-437.	1.4	18
58	Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of <i>CTNNB1</i> Mutational Status. <i>Clinical Cancer Research</i> , 2020, 26, 6277-6283.	7.0	18
59	Higher toxicity with 42 Gy in 10 fractions as a total dose for 3D-conformal accelerated partial breast irradiation: results from a dose escalation phase II trial. <i>Radiation Oncology</i> , 2012, 7, 141.	2.7	17
60	Tumor Assessment Criteria in Phase I Trials: Beyond RECIST. <i>Journal of Clinical Oncology</i> , 2013, 31, 395-395.	1.6	17
61	Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey. <i>Lung Cancer</i> , 2019, 136, 145-147.	2.0	17
62	Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer Patients: Secondary Findings From the Prospective Randomized Phase 3 CONVERT Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 294-297.	1.1	17
63	Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand?. <i>Lung Cancer</i> , 2021, 162, 96-105.	2.0	17
64	Indications and Parameters Around Postoperative Radiation Therapy for Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 556-566.	1.6	17
65	Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival. <i>Journal of Neuro-Oncology</i> , 2015, 123, 307-314.	2.9	16
66	Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 116-124.	0.6	16
67	A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 15924-15933.	1.8	16
68	Reappraisal of clinical outcome in adult medulloblastomas with emphasis on patterns of relapse. <i>British Journal of Neurosurgery</i> , 2010, 24, 460-467.	0.8	15
69	Reversible Posterior Leukoencephalopathy Syndrome Induced by Axitinib. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e33-e34.	1.9	15
70	Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients. <i>Oncotarget</i> , 2016, 7, 25549-25557.	1.8	15
71	1-week hypofractionated adjuvant whole-breast radiotherapy: towards a new standard?. <i>Lancet, The</i> , 2020, 395, 1588-1589.	13.7	15
72	Sinonasal squamous cell carcinoma without clinical lymph node involvement. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 537-544.	2.0	14

#	ARTICLE	IF	CITATIONS
73	Candidate immune biomarkers for radioimmunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 58-68.	7.4	14
74	Thoracic radiotherapy in small cell lung cancer—a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2059-2070.	2.8	14
75	Carcinomas of an unknown primary site: a curable disease?. <i>Annals of Oncology</i> , 2008, 19, 1657-1658.	1.2	13
76	Loco-regional Control After Neo-adjuvant Chemotherapy and Conservative Treatment for Locally Advanced Breast Cancer Patients. <i>Breast Journal</i> , 2014, 20, 381-387.	1.0	13
77	The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell lines— <i>in-vitro</i> and <i>in-vivo</i> xenografts. <i>Anti-Cancer Drugs</i> , 2013, 24, 599-608.	1.4	12
78	Renal angiomyolipomas: At least two diseases. A series of patients treated at two European institutions. <i>European Journal of Surgical Oncology</i> , 2017, 43, 831-836.	1.0	12
79	Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 25189-25199.	1.8	12
80	Squamous cell carcinoma of the larynx with subglottic extension: is larynx preservation possible?. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 654-660.	2.0	11
81	Leukocytosis, prognosis biomarker in locally advanced head and neck cancer patients after chemoradiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2018, 12, 8-15.	1.7	11
82	Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. <i>European Journal of Cancer</i> , 2020, 135, 103-112.	2.8	11
83	Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 602-613.	0.8	11
84	PD-1 inhibitor and chemotherapy with concurrent IRradiation at VARied tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial. <i>Clinical Lung Cancer</i> , 2022, 23, e252-e256.	2.6	10
85	Clear Cell Adenocarcinoma of the Female Genital Tract: Long-Term Outcome and Fertility Aspects After Brachytherapy Aimed at a Conservative Treatment. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1378-1382.	2.5	9
86	Early PSA level decline is an independent predictor of biochemical and clinical control for salvage postprostatectomy radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 108.e15-108.e20.	1.6	9
87	¹⁸ F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer. <i>Oral Oncology</i> , 2015, 51, 370-375.	1.5	9
88	Postoperative Outcome of Surgery with Pancreatic Resection for Retroperitoneal Soft Tissue Sarcoma: Results of a Retrospective Bicentric Analysis on 50 Consecutive Patients. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2299-2306.	1.7	9
89	Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane—based induction chemotherapy in locally advanced head and neck cancer. <i>Head and Neck</i> , 2016, 38, E905-10.	2.0	8
90	How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3486-3502.	2.8	8

#	ARTICLE	IF	CITATIONS
91	Is there a withdrawal syndrome with abiraterone acetate (AA)? Journal of Clinical Oncology, 2013, 31, 89-89.	1.6	8
92	Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1â€“CREB1 fusion and ALK overexpression. Annals of Oncology, 2022, 33, 848-850.	1.2	8
93	Curativeâ€“intended Treatment of Squamous Cell Anal Carcinoma in Elderly Adults. Journal of the American Geriatrics Society, 2012, 60, 1993-1994.	2.6	7
94	Features of cancer management in obese patients. Critical Reviews in Oncology/Hematology, 2013, 85, 193-205.	4.4	7
95	Treatment of squamous cell carcinoma of the posterior pharyngeal wall: Radiotherapy versus surgery. Head and Neck, 2016, 38, E1722-9.	2.0	7
96	Is dose de-escalation possible in sarcoma patients treated with enlarged limb sparing resection?. Radiotherapy and Oncology, 2018, 126, 493-498.	0.6	7
97	Radiosurgery in Patients With Small Cell Lung Cancer With Brain Metastases. JAMA Oncology, 2020, 6, 1037.	7.1	7
98	Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma. Cancer Medicine, 2021, 10, 230-236.	2.8	7
99	Analysis of Radiation Dose/Volume Effect Relationship for Anorectal Morbidity in Children Treated for Pelvic Malignancies. International Journal of Radiation Oncology Biology Physics, 2021, 109, 231-241.	0.8	7
100	Tumour motion management in lung cancer: a narrative review. Translational Lung Cancer Research, 2021, 10, 2011-2017.	2.8	7
101	Can radiation-recall predict long lasting response to immune checkpoint inhibitors?. Radiotherapy and Oncology, 2021, 154, 125-127.	0.6	7
102	¹⁸ F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [¹⁸ F]FDG PET-MRI data. EJNMMI Research, 2020, 10, 88.	2.5	7
103	Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. Investigational New Drugs, 2012, 30, 1116-1120.	2.6	6
104	Clinical and Therapeutic Aspects in Elderly Patients with Merkel Cell Carcinoma: Special Focus on Radiotherapy. Journal of the American Geriatrics Society, 2009, 57, 1946-1947.	2.6	5
105	Preventing radiotherapy-induced side effects on deep brain stimulators: the need for a multidisciplinary management. British Journal of Neurosurgery, 2014, 28, 107-109.	0.8	5
106	In Regard to Koshy et al. International Journal of Radiation Oncology Biology Physics, 2015, 92, 945-946.	0.8	5
107	Prophylactic cranial irradiation or no prophylactic cranial irradiation in metastatic small cell lung cancer: is it a relevant question once again?. Journal of Thoracic Disease, 2017, 9, 4157-4161.	1.4	5
108	Are We Ready to Safely Combine Antiâ€“PD-1/PD-L1 with Cranial Irradiation in Nonâ€“Small Cell Lung Cancer Patients?. Journal of Thoracic Oncology, 2018, 13, 475-477.	1.1	5

#	ARTICLE	IF	CITATIONS
109	Consistent Margin-Status Reporting in Soft Tissue Sarcoma Is Essential to Establish Risk-Adapted Strategies Integrating Biology and Histotype in Perioperative Treatments. <i>Journal of Clinical Oncology</i> , 2018, 36, 2357-2358.	1.6	5
110	Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter?. <i>Lung Cancer</i> , 2020, 139, 216-218.	2.0	5
111	Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib. <i>Cancer Management and Research</i> , 2021, Volume 13, 2805-2810.	1.9	5
112	In Regard to Yang et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 811.	0.8	4
113	First case report of intrathecal panitumumab for treatment of meningeal carcinomatosis in an EGFR mutant lung adenocarcinoma patient. <i>Lung Cancer</i> , 2013, 80, 113-114.	2.0	4
114	Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas. <i>Anti-Cancer Drugs</i> , 2014, 25, 1220-1226.	1.4	4
115	Plerixafor for the Treatment of WHIM Syndrome. <i>New England Journal of Medicine</i> , 2019, 380, e25.	27.0	4
116	Fully Integrated Quantitative Multiparametric Analysis of Non- ¹⁸ F Small Cell Lung Cancer at 3-T PET/MRI. <i>Clinical Nuclear Medicine</i> , 2021, 46, e440-e447.	1.3	4
117	Surgical management of soft tissue tumors of the abdominal wall: A retrospective study in a high-volume sarcoma center. <i>Journal of Surgical Oncology</i> , 2021, 124, 679-686.	1.7	4
118	Postgraduate oncology educational shifts during the COVID-19 pandemic: results of faculty and medical student surveys. <i>ESMO Open</i> , 2022, 7, 100451.	4.5	4
119	FOLFIRINOX in Locally Advanced Pancreatic Cancer. <i>Pancreas</i> , 2012, 41, 973-974.	1.1	3
120	Reappraisal of the Role of Bevacizumab in the Therapeutic Strategy in Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 147-152.	1.9	3
121	Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use. <i>Journal of Chemotherapy</i> , 2014, 26, 253-255.	1.5	3
122	Cannabis use and lung cancer: time to stop overlooking the problem?. <i>European Respiratory Journal</i> , 2021, 57, 2004132.	6.7	3
123	Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?. <i>Frontiers in Immunology</i> , 2021, 12, 745146.	4.8	3
124	Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
125	Practice changing data and emerging concepts from recent radiation therapy randomised clinical trials. <i>European Journal of Cancer</i> , 2022, 171, 242-258.	2.8	3
126	Current trials of cytotoxic and targeted agents in breast cancer: the caveat of radiotherapy. <i>Annals of Oncology</i> , 2011, 22, 1243-1244.	1.2	2

#	ARTICLE	IF	CITATIONS
127	Focal 3D conformal high-dose hypofractionated radiotherapy for brain metastases. Melanoma Research, 2012, 22, 406-409.	1.2	2
128	Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?. OncoTargets and Therapy, 2013, 6, 95.	2.0	2
129	Stereotactic ablative body radiation therapy or surgery for operable early non-small cell lung cancer patients: bound hand and foot to evidence. Journal of Thoracic Disease, 2017, 9, 482-484.	1.4	2
130	Hippocampal Avoidance Whole-Brain Radiotherapy (WBRT) Versus WBRT in Patients With Brain Metastases: Were Hippocampi the Only Difference?. Journal of Clinical Oncology, 2020, 38, 3453-3454.	1.6	2
131	Could Protons Promote Tumor Control by Avoiding Lymphopenia?. Journal of Thoracic Oncology, 2021, 16, e39-e41.	1.1	2
132	Volumetric modulated arc radiotherapy for limited osteosclerotic myeloma. World Journal of Radiology, 2013, 5, 173.	1.1	2
133	Can a Cure Be Achieved with Taxane-Based Chemotherapy plus Surgery in Patients with Primary Mediastinal Non-Seminomatous Germ Cell Tumors and Progression or Relapse Despite First-Line Chemotherapy?. Onkologie, 2010, 33, 119-120.	0.8	1
134	Poorer outcome in Polynesian patients with prostate cancer treated with definitive conformational radiation therapy. Radiotherapy and Oncology, 2011, 101, 502-507.	0.6	1
135	Pentoxifylline to avoid radiation-induced cardiotoxicity: from NF- κ B to beyond - a reply to M. Halle and P. Hall and P. Tornvall. Journal of Internal Medicine, 2011, 270, 487-488.	6.0	1
136	Computed Tomography-Based Simulation for Thoracic Radiation Therapy: Technical Advance or Clinical Evidence?. Journal of Clinical Oncology, 2011, 29, 4335-4336.	1.6	1
137	Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials. Oncology Research and Treatment, 2013, 36, 357-362.	1.2	1
138	Individualizing Adjuvant Radiotherapy in Patients With Breast Cancer: Let's Not Get Ahead of Ourselves. Journal of Clinical Oncology, 2014, 32, 3339-3340.	1.6	1
139	Activity of erlotinib in patients (pts) with advanced chordoma: A retrospective study.. Journal of Clinical Oncology, 2021, 39, 11528-11528.	1.6	1
140	Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer. Lancet Oncology, The, 2021, 22, e220.	10.7	1
141	Prospective evaluation of intensity-modulated radiotherapy toxicity in extremity soft tissue sarcomas patients: A role for irradiated healthy soft tissue volume?. Clinical and Translational Radiation Oncology, 2021, 29, 79-84.	1.7	1
142	Stage III NSCLC in Low- and Middle-Income Countries: Where Are We in 2021?. Journal of Thoracic Oncology, 2021, 16, 1605-1606.	1.1	1
143	Inoperable scalp cutaneous angiosarcoma: Complete response after definitive external beam radiation therapy - brachytherapy association. Oral Oncology, 2022, 125, 105715.	1.5	1
144	Radiotherapy tumor volume for limited-stage small cell lung cancer: less is more. Annals of Translational Medicine, 2020, 8, 1114-1114.	1.7	1

#	ARTICLE	IF	CITATIONS
145	Concerns about cardiotoxicity in the HERA trial. Lancet, The, 2017, 390, 2767.	13.7	0
146	Multimodal approach: combining radiation therapy with immunotherapy in solid tumors. Future Oncology, 2020, 16, 1669-1671.	2.4	0
147	Drugâ€“Radiotherapy Combination Trial Developmentsâ€“Response. Clinical Cancer Research, 2021, 27, 356-356.	7.0	0
148	Activity of single-agent gemcitabine in patients (pts) with advanced angiosarcoma: A retrospective study.. Journal of Clinical Oncology, 2021, 39, e23547-e23547.	1.6	0
149	Analyzing Oxidative Stress in Murine Intestinal Organoids using Reactive Oxygen Species-Sensitive Fluorogenic Probe. Journal of Visualized Experiments, 2021, , .	0.3	0
150	Brain Metastases. , 2015, , 245-255.		0
151	Microbiote et rÃ©gÃ©nÃ©ration de lâ€™Ã©pithÃ©lium intestinal : des signaux cryptiques dÃ©cryptÃ©s dans la crypte. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 1393-1400.	0,0	0
152	Radiotherapy tumor volume for limited-stage small cell lung cancer: less is more. Annals of Translational Medicine, 2020, 8, 1114.	1.7	0